Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs

This article was originally published in PharmAsia News

Executive Summary

Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher

You may also be interested in...



Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex

TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S

Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex

TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S

Eisai Posts First Ever Net Loss Due To Heavy Investment

TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel